Obesity Is Associated with Inferior Clinical Treatment Outcomes in Inflammatory Bowel Disease: A Nationwide Dutch Registry Study
Obesity was associated with lower steroid-free clinical remission at week 24. Obese patients with IBD should be encouraged to lose weight not only to improve their overall health, but also to optimize their treatment outcomes.
Authors
- Mark Löwenberg (ORCID: https://orcid.org/0000-0002-4975-9945)
- Sander van der Marel
- Annemarie C. de Vries (ORCID: https://orcid.org/0000-0002-3988-9201)
- Zlatan Mujagic (ORCID: https://orcid.org/0000-0001-5211-0381)
- Alexander Bodelier (ORCID: https://orcid.org/0000-0002-2329-9995)
- Andrea E. van der Meulen‐de Jong (ORCID: https://orcid.org/0000-0001-9353-5431)
- Marijn C. Visschedijk (ORCID: https://orcid.org/0000-0001-7277-7677)
- Marjolijn Duijvestein (ORCID: https://orcid.org/0000-0003-4814-9376)
- Tessa Straatmijer (ORCID: https://orcid.org/0000-0001-6989-5226)
- Rachel West (ORCID: https://orcid.org/0000-0003-1914-9393)
- Fiona van Schaik
- Dorien Oomkens
Institutions
- Leiden University (NL)
- University Medical Center Groningen (NL)
- Radboud University Nijmegen (NL)
- University of Groningen (NL)
- Maastricht University Medical Centre (NL)
- Radboud University Medical Center (NL)
- University Medical Center Utrecht (NL)
- Sint Franciscus Gasthuis (NL)
- Medisch Centrum Haaglanden (NL)
- Amphia Ziekenhuis (NL)
- Radboud Institute for Molecular Life Sciences (NL)
- Erasmus University Rotterdam (NL)
Publication Details
- Journal
- Digestive Diseases and Sciences
- Published
- 2025-04-16
- DOI
- https://doi.org/10.1007/s10620-025-09052-5
- Citations
- 4
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 7.27
Funders
- Eli Lilly and Company
- Pfizer
- ZonMw
- Tillotts Pharma
- Dr. Falk Pharma
- Cilag